Brinzolamide
| Clinical data | |
|---|---|
| Pronunciation | brin ZOH la mide |
| Trade names | Azopt |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601233 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Ophthalmic |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Absorbed systemically, but below detectable levels (less than 10 ng/mL) |
| Protein binding | ~60% |
| Elimination half-life | 111 days |
| Excretion | Kidney (60%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.149.376 |
| Chemical and physical data | |
| Formula | C12H21N3O5S3 |
| Molar mass | 383.50 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Brinzolamide (trade name Azopt) is a carbonic anhydrase inhibitor used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Brinzolamide was approved as a generic medication in the United States in November 2020.